A study evaluating circulating tumor cell (CTC)-based gene expression for predicting resistance to Abiraterone and Enzalutamide in Patients with metastatic castration resistant prostate cancer (mCRPC)

Trial Profile

A study evaluating circulating tumor cell (CTC)-based gene expression for predicting resistance to Abiraterone and Enzalutamide in Patients with metastatic castration resistant prostate cancer (mCRPC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 New trial record
    • 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top